Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - [AstraZeneca Plc]

22 May 2014 15:16

RNS Number : 8533H
Viking Global Investors LP
22 May 2014
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

Viking Global Investors LP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

n/a

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AstraZeneca Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

n/a

(e) Date position held/dealing undertaken:

21 May 2014

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

USD 0.25 ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0

0

0

(2) Derivatives (other than options):

19,602,422

1.55

0

0

(3) Options and agreements to purchase/sell:

0

0

0

0

 

TOTAL:

19,602,422

1.55

0

0

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

USD 0.25 ordinary

CFD

 

Reducing a long position

123,000

GBP 44.39500

USD 0.25 ordinary

CFD

 

Reducing a long position

115,600

GBP 44.34500

USD 0.25 ordinary

CFD

 

Reducing a long position

120,000

GBP 44.22074

USD 0.25 ordinary

CFD

 

Reducing a long position

64,800

GBP 44.20000

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

22 May 2014

Contact name:

Daniel Taub

Telephone number:

203-863-5000

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETPGUAGAUPCGCP
Date   Source Headline
6th Mar 20177:00 amRNSDirectorate Change
3rd Mar 20177:00 amRNSALLIANCE WITH SANOFI PASTEUR FOR MEDI8897
1st Mar 20174:30 pmRNSTotal Voting Rights
28th Feb 20177:02 amRNSFDA approves once-daily Qtern for type-2 diabetes
24th Feb 201712:32 pmRNSCHMP positive opinion for ZS-9 in hyperkalaemia
20th Feb 20177:00 amRNSAZ licenses Zoladex to TerSera for the US & Canada
17th Feb 20177:00 amRNSLynparza positive in metastatic BRCA breast cancer
16th Feb 201712:01 pmRNSSILIQ (BRODALUMAB) APPROVED BY US FDA
2nd Feb 20177:00 amRNSAZN: FY16 and Q4 2016 Results
1st Feb 20174:00 pmRNSTotal Voting Rights
26th Jan 201710:00 amRNSSYMBICORT GRANTED PAEDIATRIC EXCLUSIVITY IN THE US
17th Jan 20177:00 amRNSAZ 1st-line lung cancer immuno-oncology programme
3rd Jan 20174:00 pmRNSTotal Voting Rights
23rd Dec 20167:00 amRNSAZ COMPLETES SALE OF ANTIBIOTICS BUSINESS
16th Dec 20161:00 pmRNSDirector/PDMR Shareholding
9th Dec 20163:05 pmRNSFDA accepts durvalumab for BLA in bladder cancer
6th Dec 20169:30 amRNSTagrisso data shows superiority over chemotherapy
5th Dec 20167:00 amRNSAZ completes agreement for Rhinocort Aqua rights
1st Dec 20164:00 pmRNSBlock listing Interim Review
1st Dec 20163:00 pmRNSTotal Voting Rights
22nd Nov 20167:00 amRNSAZ head and neck cancer trials resume enrolment
17th Nov 20167:00 amRNSAZ out-licensing deal with Allergan completed
10th Nov 20167:04 amRNSYear-To-Date and Q3 2016 Results
9th Nov 20167:00 amRNSDirectorate Change
1st Nov 20163:30 pmRNSDealing by Person Closely Associated
1st Nov 20163:00 pmRNSTotal Voting Rights
31st Oct 20161:47 pmRNSAZ completes US Aralez agreement for Toprol-XL
27th Oct 20164:51 pmRNSAstraZeneca Head and Neck Cancer Trials
26th Oct 20167:00 amRNSPositive results in AstraZeneca Lynparza trial
18th Oct 20167:00 amRNSFDA accepts for review ZS-9 NDA for hyperkalaemia
7th Oct 20167:00 amRNSAZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE US
4th Oct 20167:05 amRNSAZ agreement with Aralez for Toprol-XL in US
4th Oct 20167:00 amRNSAstraZeneca reports top-line EUCLID results in PAD
3rd Oct 20163:00 pmRNSTotal Voting Rights
3rd Oct 20167:00 amRNSMedImmune out-licenses medicine to Allergan
28th Sep 20167:00 amRNSCHANGE TO ASTRAZENECA BOARD OF DIRECTORS
26th Sep 20164:00 pmRNSDirector/PDMR Shareholding
22nd Sep 201611:00 amRNSDirector Declaration
1st Sep 20162:30 pmRNSTotal Voting Rights
1st Sep 20167:00 amRNSAstraZeneca Completes Aspen Agreement
24th Aug 20167:00 amRNSAZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER
18th Aug 20161:00 pmRNSDirector Declaration
16th Aug 20167:00 amRNSAstraZeneca completes agreement with LEO Pharma
10th Aug 20162:41 pmRNSASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA
9th Aug 20167:00 amRNSASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL
1st Aug 20162:30 pmRNSTotal Voting Rights
1st Aug 201611:00 amRNSDirector/PDMR Shareholding
28th Jul 20167:00 amRNSAZN: H1 2016 Results
27th Jul 20169:00 amRNSNotice of Results
19th Jul 20162:15 pmRNSQTERN (saxa/dapa) EU approved for type-2 diabetes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.